Literature DB >> 14693695

Nonesterified fatty acids and hepatic glucose metabolism in the conscious dog.

Mary Courtney Moore1, Shosuke Satake, Margaret Lautz, Scott A Soleimanpour, Doss W Neal, Marta Smith, Alan D Cherrington.   

Abstract

We used tracer and arteriovenous difference techniques in conscious dogs to determine the effect of nonesterified fatty acids (NEFAs) on net hepatic glucose uptake (NHGU). The protocol included equilibration ([3-(3)H]glucose), basal, and two experimental periods (-120 to -30, -30 to 0, 0-120 [period 1], and 120-240 min [period 2], respectively). During periods 1 and 2, somatostatin, basal intraportal insulin and glucagon, portal glucose (21.3 micromol.kg(-1).min(-1)), peripheral glucose (to double the hepatic glucose load), and peripheral nicotinic acid (1.5 mg.kg(-1).min(-1)) were infused. During period 2, saline (nicotinic acid [NA], n = 7), lipid emulsion (NA plus lipid emulsion [NAL], n = 8), or glycerol (NA plus glycerol [NAG], n = 3) was infused peripherally. During period 2, the NA and NAL groups differed (P < 0.05) in rates of NHGU (10.5 +/- 2.08 and 4.7 +/- 1.9 micromol.g(-1).min(-1)), respectively, endogenous glucose R(a) (2.3 +/- 1.4 and 10.6 +/- 1.0 micromol.kg(-1).min(-1)), net hepatic NEFA uptakes (0.1 +/- 0.1 and 1.8 +/- 0.2 micromol.kg(-1).min(-1)), net hepatic beta-hydroxybutyrate output (0.1 +/- 0.0 and 0.4 +/- 0.1 micromol.kg(-1).min(-1)), and net hepatic lactate output (6.5 +/- 1.7 vs. -2.3 +/- 1.2 micromol.kg(-1).min(-1)). Hepatic glucose uptake and release were 2.6 micro mol. kg(-1). min(-1) less and 3.5 micro mol. kg(-1). min(-1) greater, respectively, in the NAL than NA group (NS). The NAG group did not differ significantly from the NA group in any of the parameters listed above. In the presence of hyperglycemia and relative insulin deficiency, elevated NEFAs reduce NHGU by stimulating hepatic glucose release and suppressing hepatic glucose uptake.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693695     DOI: 10.2337/diabetes.53.1.32

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  19 in total

1.  Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver.

Authors:  P Iozzo; R Lautamaki; F Geisler; K A Virtanen; V Oikonen; M Haaparanta; H Yki-Jarvinen; E Ferrannini; J Knuuti; P Nuutila
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 2.  Regulation of hepatic glucose uptake and storage in vivo.

Authors:  Mary Courtney Moore; Katie C Coate; Jason J Winnick; Zhibo An; Alan D Cherrington
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

3.  Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo.

Authors:  Christopher J Ramnanan; Dale S Edgerton; Noelia Rivera; Jose Irimia-Dominguez; Ben Farmer; Doss W Neal; Margaret Lautz; E Patrick Donahue; Catalina M Meyer; Peter J Roach; Alan D Cherrington
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

4.  Targeting insulin to the liver corrects defects in glucose metabolism caused by peripheral insulin delivery.

Authors:  Dale S Edgerton; Melanie Scott; Ben Farmer; Phillip E Williams; Peter Madsen; Thomas Kjeldsen; Christian L Brand; Christian Fledelius; Erica Nishimura; Alan D Cherrington
Journal:  JCI Insight       Date:  2019-02-26

5.  Hepatic glycogen can regulate hypoglycemic counterregulation via a liver-brain axis.

Authors:  Jason J Winnick; Guillaume Kraft; Justin M Gregory; Dale S Edgerton; Phillip Williams; Ian A Hajizadeh; Maahum Z Kamal; Marta Smith; Ben Farmer; Melanie Scott; Doss Neal; E Patrick Donahue; Eric Allen; Alan D Cherrington
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

6.  Comparison of insulins detemir and glargine: effects on glucose disposal, hepatic glucose release and the central nervous system.

Authors:  M C Moore; M S Smith; M K Turney; S Boysen; P E Williams
Journal:  Diabetes Obes Metab       Date:  2011-09       Impact factor: 6.577

7.  Effects of 11β-hydroxysteroid dehydrogenase-1 inhibition on hepatic glycogenolysis and gluconeogenesis.

Authors:  J J Winnick; C J Ramnanan; V Saraswathi; J Roop; M Scott; P Jacobson; P Jung; R Basu; A D Cherrington; D S Edgerton
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

8.  Glucagon-mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability.

Authors:  Sheng-Song Chen; Tammy S Santomango; Phillip E Williams; D Brooks Lacy; Owen P McGuinness
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-02-10       Impact factor: 4.310

9.  A physiological increase in the hepatic glycogen level does not affect the response of net hepatic glucose uptake to insulin.

Authors:  Jason J Winnick; Zhibo An; Mary Courtney Moore; Christopher J Ramnanan; Ben Farmer; Masakazu Shiota; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-05-26       Impact factor: 4.310

10.  Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo.

Authors:  Dale S Edgerton; Christopher J Ramnanan; Carrie A Grueter; Kathryn M S Johnson; Margaret Lautz; Doss W Neal; Phillip E Williams; Alan D Cherrington
Journal:  Diabetes       Date:  2009-09-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.